BioCentury | Jul 21, 2008
Company News

Agendia, Ferrer sales and marketing update

...Agendia granted Grupo Ferrer's Ferrer inCode subsidiary exclusive rights to sell MammaPrint and CupPrint in Germany...
...recurrence. CupPrint identifies the primary tumor site in patients with cancer of unknown primary (CUP). CupPrint...
BioCentury | Jul 17, 2006
Clinical News

CupPrint regulatory update

...Agendia received CE Mark approval in the EU for its CupPrint test to identify the primary...
...Inc., now AviaraDx Inc. (Carlsbad, Calif.) in 2005. Agendia B.V. , Amsterdam, the Netherlands Product: CupPrint...
BioCentury | Apr 3, 2006
Company News

Agendia BV, Opaldia Ltd. sales and marketing update

...cancer patients at low and high risk of developing distant metastases over 10 years, and CupPrint...
BioCentury | Feb 7, 2005
Company News

Agendia BV, Arcturus Bioscience Inc. deal

...the TUO (tumor of unknown origin) gene expression profile. Agendia uses the profile in its CupPrint...
BioCentury | Feb 2, 2005
Company News

Agendia acquires TUO-gene expression profile

...the TUO (tumor of unknown origin) gene expression profile. Agendia uses the profile in its CupPrint...
Items per page:
1 - 5 of 5